Sponsors

BBI and BioAgilytix partner for bioanalytical testing

BBI Solutions a trusted expert provider of end-to-end solutions for the development of high-performance assays, has signed a partnership agreement with BioAgilytix, a leading global bioanalytical laboratory. The partnership will integrate BBI’s ability to produce high-quality custom antibody reagents for a variety of testing applications with BioAgilytix’s bioanalytical testing services.

This approach simplifies a crucial step in bioanalytical testing for pharma and biopharma sponsors. The more streamlined service will ultimately help bring customers one step closer to market for their innovative therapies.

As part of bioanalytical testing - a key aspect of bringing any new therapy to market - drug developers often need a variety of antibody reagents tailored to their candidate therapy, and for a range of testing applications. However, developing and securing a reliable supply of fit-for-purpose, customised antibody reagents is not easy. This step is often managed in isolation from other aspects of a bioanalytical testing programme, which can further complicate the process.

The new partnership between BioAgilytix and BBI’s antibody development centre, MBS, will address this challenge. BBI’s proven, efficient mono- and polyclonal custom antibody reagent development services will be seamlessly integrated with BioAgilytix’s bioanalytical testing solutions. This simplifies the experience for bioanalytical testing customers, who can now work with a single provider for swift access to high-quality, custom antibody reagents suitable across testing applications.

"This partnership further strengthens an already excellent relationship with BioAgilytix through which BBI can utilise the depth of its antibody development expertise to provide custom solutions to its clients," said Mathew Hobbs, Chief Commercial Officer, BBI. "By streamlining a critical and complex step in bioanalytical testing, we’re helping customers get one step closer to delivering their innovative therapies to patients."

To find out more about the combined service offering from BBI and BioAgilytix, visit https://www.bioagilytix.com/about/partners/.

 

Latest Issues

11th Digital Pathology & AI Congress: Europe

Hilton London Metropole, 255 Edgware Road, London, W2 1JU
11-12 December, 2024

Microbiology Society Annual Conference 2025

Liverpool Arena and Convention Centre
31 March - 3 April, 2025

BSMT Annual Microbiology Conference

RAF Museum, Hendon, London NW9 5LL
15 May, 2025

Ghent Pathology 2025

ICC Ghent, Belgium
24-26 June, 2025

37th European Congress of Pathology

ACV, Vienna, Austria
6 -10 September, 2025